Latest 2 stories · newest Sep 22, 2026
Lexeo is entering a merger with Mantle Therapeutics, according to an agreement signed on September 16, 2026. The deal represents a significant transaction in the biotech sector.
Lexeo Therapeutics announced finalization of the SUNRISE-FA 2 pivotal trial protocol for LX2006 in Friedreich ataxia, with first patient enrollment expected by end of Q2 2026 and BLA submission targeted for 2028. The open-label study design with 13 treated and 13 untreated control participants posit…
The same LXEO feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/LXEO/newsSTART FREE